CHECK YOUR PRODUCT
Cart0

Tirzepatide

Tirzepatide is a dual agonist: it stimulates the GLP-1 receptor and the GIP receptor at the same time. In registered form it is a prescription medicine; what is sold here is research material, not a medicine.

What is in the vial

Tirzepatide comes here in three versions: a 20 mg vial from Genheal, a 20 mg vial from Bio-Peptide with two solvent ampoules, and a 40 mg ready-to-use pen from Nouveaux Ltd. Set a single 20 mg vial against the registered medicine, where the highest weekly dose in the weight trials was 15 mg, and the scale of a single vial becomes clear. A 20 mg vial with 2 ml of bacteriostatic water gives 10 mg per millilitre, which means very small volumes per administration and a real risk of arithmetic errors: see reconstitution and syringe units.

What the trials showed

In SURMOUNT-1, tirzepatide at 15 mg reduced body weight by 20.9 percent over 72 weeks, against 3.1 percent on placebo. In SURMOUNT-5, the only head-to-head comparison in this group, it reached 20.2 percent against 13.7 percent for semaglutide over 72 weeks, with waist circumference falling 18.4 cm against 13.0 cm.

Fewer people stopped treatment because of gastrointestinal symptoms on tirzepatide than on semaglutide in that trial: 2.7 percent against 5.6 percent.

Why the second receptor

GIP receptor stimulation adds appetite-suppressing neural circuits and thermogenesis to what GLP-1 already does. Curiously, blocking the same receptor also reduces body weight, by a different route; both directions are described in the incretin guide and in more detail in why tirzepatide acts on two receptors.

Status

Approved by the FDA in May 2022, sold as Mounjaro for type 2 diabetes and Zepbound for obesity. In Poland the registered product is Mounjaro, on prescription. Research material is not that product.

Why it is prescription-only, and what the prescription actually covers, is set out in the guide on prescription status. We publish no dosing schedules: the escalation used in the trials belongs to supervised treatment.

Handling and verification

The vials are supplied as lyophilised powder; the Nouveaux Ltd. pen holds a ready solution, which is less stable than powder and is kept in the fridge. Storage rules change once the powder is dissolved: see storage. Check the code under the hologram and the batch certificate as described in check your product. We ship within Poland and abroad; outside Poland shipping costs 30 EUR paid in advance or 80 EUR cash on delivery, the same for every country. Details: shipping and payments.

Questions

Is tirzepatide stronger than semaglutide?

In the only head-to-head trial, yes: 20.2 percent against 13.7 percent over 72 weeks, with a larger fall in waist circumference.

What does the GIP receptor add?

Appetite-suppressing neural circuits and thermogenesis, on top of the GLP-1 effect.

Is this Mounjaro or Zepbound?

No. Those are registered medicines. This vial is research material, without their dose, controls or product information.

Were side effects worse than with semaglutide?

Fewer people stopped because of gastrointestinal symptoms on tirzepatide in the head-to-head trial: 2.7 percent against 5.6 percent.